Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL)
- PMID: 16393718
- DOI: 10.1080/02770900500369868
Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL)
Abstract
This investigation evaluated variability in asthma-related quality-of-life (ARQL) outcomes among patients randomized to omalizumab or placebo. Pooled data on the Asthma Quality of Life Questionnaire (AQLQ) from two trials were used (n = 948). Variability in ARQL outcomes was determined by categorizing AQLQ score changes according to minimal clinically important difference (MCID: 0.5 points) and large clinically important difference (LCID: 1.5 points) score changes. A greater proportion of patients achieved improvement in every domain of AQLQ scores during all periods with omalizumab compared with placebo. Omalizumab-treated patients showed greater clinically important improvement in ARQL compared with patients receiving placebo.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical